These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
772 related articles for article (PubMed ID: 31323222)
21. Cumambrin A prevents OVX-induced osteoporosis Zhou L; Liu Q; Hong G; Song F; Zhao J; Yuan J; Xu J; Tan RX; Tickner J; Gu Q; Xu J FASEB J; 2019 Jun; 33(6):6726-6735. PubMed ID: 30807230 [TBL] [Abstract][Full Text] [Related]
22. Yukmijihwang-tang inhibits receptor activator for nuclear Factor-κB ligand-induced osteoclast differentiation. Shim KS; Ma CJ; Kim DS; Ma JY J Med Food; 2011 Nov; 14(11):1439-47. PubMed ID: 21883017 [TBL] [Abstract][Full Text] [Related]
23. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages. Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379 [TBL] [Abstract][Full Text] [Related]
24. Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways. Gan K; Yang L; Xu L; Feng X; Zhang Q; Wang F; Tan W; Zhang M Int Immunopharmacol; 2016 Jun; 35():294-300. PubMed ID: 27085680 [TBL] [Abstract][Full Text] [Related]
25. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation. Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351 [TBL] [Abstract][Full Text] [Related]
26. Abeliophyllum distichum Nakai alleviates postmenopausal osteoporosis in ovariectomized rats and prevents RANKL-induced osteoclastogenesis in vitro. Kim EY; Kim JH; Kim M; Park JH; Sohn Y; Jung HS J Ethnopharmacol; 2020 Jul; 257():112828. PubMed ID: 32268206 [TBL] [Abstract][Full Text] [Related]
27. Matrine prevents bone loss in ovariectomized mice by inhibiting RANKL-induced osteoclastogenesis. Chen X; Zhi X; Pan P; Cui J; Cao L; Weng W; Zhou Q; Wang L; Zhai X; Zhao Q; Hu H; Huang B; Su J FASEB J; 2017 Nov; 31(11):4855-4865. PubMed ID: 28739641 [TBL] [Abstract][Full Text] [Related]
28. Combination of IL-6 and sIL-6R differentially regulate varying levels of RANKL-induced osteoclastogenesis through NF-κB, ERK and JNK signaling pathways. Feng W; Liu H; Luo T; Liu D; Du J; Sun J; Wang W; Han X; Yang K; Guo J; Amizuka N; Li M Sci Rep; 2017 Jan; 7():41411. PubMed ID: 28128332 [TBL] [Abstract][Full Text] [Related]
29. Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways. Chen K; Yan Z; Wang Y; Yang Y; Cai M; Huang C; Li B; Yang M; Zhou X; Wei X; Yang C; Chen Z; Zhai X; Li M Biomed Pharmacother; 2020 Jun; 126():110067. PubMed ID: 32272431 [TBL] [Abstract][Full Text] [Related]
30. Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways. He Y; Zhang Q; Shen Y; Chen X; Zhou F; Peng D Biochem Biophys Res Commun; 2014 Jul; 449(3):344-50. PubMed ID: 24845381 [TBL] [Abstract][Full Text] [Related]
31. Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo. Zhai ZJ; Li HW; Liu GW; Qu XH; Tian B; Yan W; Lin Z; Tang TT; Qin A; Dai KR Br J Pharmacol; 2014 Feb; 171(3):663-75. PubMed ID: 24125472 [TBL] [Abstract][Full Text] [Related]
32. Urolithin B suppressed osteoclast activation and reduced bone loss of osteoporosis via inhibiting ERK/NF-κB pathway. Li Y; Zhuang Q; Tao L; Zheng K; Chen S; Yang Y; Feng C; Wang Z; Shi H; Shi J; Fang Y; Xiao L; Geng D; Wang Z Cell Prolif; 2022 Oct; 55(10):e13291. PubMed ID: 35708050 [TBL] [Abstract][Full Text] [Related]
33. CaMKII(δ) regulates osteoclastogenesis through ERK, JNK, and p38 MAPKs and CREB signalling pathway. Lu DZ; Dong W; Feng XJ; Chen H; Liu JJ; Wang H; Zang LY; Qi MC Mol Cell Endocrinol; 2020 May; 508():110791. PubMed ID: 32173349 [TBL] [Abstract][Full Text] [Related]
34. Diarylheptanoid from Curcuma comosa Roxb. suppresses RANKL-induced osteoclast differentiation by decreasing NFATc1 and c-Fos expression via MAPK pathway. Chawalitpong S; Sornkaew N; Suksamrarn A; Palaga T Eur J Pharmacol; 2016 Oct; 788():351-359. PubMed ID: 27523282 [TBL] [Abstract][Full Text] [Related]
35. Dencichine prevents ovariectomy-induced bone loss and inhibits osteoclastogenesis by inhibiting RANKL-associated NF-κB and MAPK signaling pathways. Cang D; Zou G; Yang C; Shen X; Li F; Wu Y; Ji B J Pharmacol Sci; 2021 Aug; 146(4):206-215. PubMed ID: 34116734 [TBL] [Abstract][Full Text] [Related]
36. Longan fruit increase bone mineral density in zebrafish and ovariectomized rat by suppressing RANKL-induced osteoclast differentiation. Son Y; Lee EM; Lee DY; Lee JH; Oh S Phytomedicine; 2019 Jun; 59():152910. PubMed ID: 30978650 [TBL] [Abstract][Full Text] [Related]
37. Chaenomelis fructus inhibits osteoclast differentiation by suppressing NFATc1 expression and prevents ovariectomy-induced osteoporosis. Kim M; Kim HS; Kim JH; Kim EY; Lee B; Lee SY; Jun JY; Kim MB; Sohn Y; Jung HS BMC Complement Med Ther; 2020 Feb; 20(1):35. PubMed ID: 32024503 [TBL] [Abstract][Full Text] [Related]
38. Glycyrrhizin improves bone metabolism in ovariectomized mice via inactivating NF-κB signaling. Tang Y; Lv XL; Bao YZ; Wang JR Climacteric; 2021 Jun; 24(3):253-260. PubMed ID: 33084419 [TBL] [Abstract][Full Text] [Related]
39. Platycodin D Inhibits Osteoclastogenesis by Repressing the NFATc1 and MAPK Signaling Pathway. Choi JH; Han Y; Kim YA; Jin SW; Lee GH; Jeong HM; Lee HS; Chung YC; Lee YC; Kim EJ; Lee KY; Jeong HG J Cell Biochem; 2017 Apr; 118(4):860-868. PubMed ID: 27739107 [TBL] [Abstract][Full Text] [Related]
40. Yukmijihwang-Tang Suppresses Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-Induced Osteoclast Differentiation and Prevents Ovariectomy (OVX)-Mediated Bone Loss. Han SY; Kim YK Molecules; 2021 Dec; 26(24):. PubMed ID: 34946658 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]